Table 1.
Baseline characteristics in HIV-1 infected patients who are antiretroviral-naïve (n = 18) or on lopinavir-based antiretroviral therapy (n = 16)
| Parameter | ARV-Naïve group | Lopinavir group | p value |
|---|---|---|---|
| Sex female n (%) | 17 (94 %) | 11 (69 %) | 0.078 |
| Age (years) | 27 (25–32) | 37 (33–41) | <0.0001 |
| Total lumefantrine dose (mg/kg) | 49.7 (43.0–52.4) | 46.5 (41.4–51.9) | 0.72 |
| Weight (kg) | 58 (55–67) | 62 (56–70) | 0.72 |
| Albumin (g/L) | 40 (39–44) | 43 (41.5–44) | 0.14 |
| Alkaline phosphatase (U/L) | 57.5 (50–69) | 69.5 (59–88) | 0.09 |
| Gamma glutamyltransferase (U/L) | 40 (39–44) | 43 (42–44) | 0.03 |
| Alanine transaminase (U/L) | 15 (13–29) | 26 (18–44) | 0.72 |
| Aspartate transaminase (U/L) | 22 (14–28) | 19 (17–30) | 0.59 |
| Mean corpuscular volume (fL) | 86.7 (85–91) | 100.95 (98–110) | 0.0001 |
| Concomitant cotrimoxazole n (%) | 6 (33 %) | 5 (31 %) | 1.0 |
| CD4+ count (×106/L) | 356 (260–507) | 375 (296–590) | 0.7 |
| HIV viral load (copies/mL) | log10 3.76 (3.0–4.1) | <50 copies/μL | 0.0005 |
Values are shown as medians (interquartile ranges [IQRs]) or n (%). Statistical significance (p values) calculated using the Kruskal-Wallis test or chi-squared test, as appropriate